Two of Sirna Therapeutics’ senior executives have left the company following its recent acquisition by Merck, RNAi News has learned.
According to Bharat Chowrira, Sirna’s vice president of legal affairs and general counsel, the company’s CFO Greg Weaver and senior vice president of corporate development Michael French have left to pursue other opportunities.
Additional details were not available.
Earlier this month, Nektar Pharmaceuticals said that it had tapped Sirna’s former President and CEO Howard Robin to be its new president and CEO.
The US Food and Drug Administration has promoted deputy commissioner Janet Woodcock to chief medical officer, a newly created spot. She will retain her duties as deputy commissioner, the FDA said.
In these positions, Woodcock will be responsible for scientific and planning-related operations, including organizing, directing, staffing, coordinating, and planning.
Cyntellect has appointed three new members to its scientific advisory board.
The new members include Alan Aderem, an immunologist and cell biologist who worked at the University of Washington, and former head of the signal transduction laboratory at The Rockefeller University; Charles Cantor, chief scientific officer at Sequenom and former chair and professor of biomedical engineering at Boston University; and Michael Hanley, vice president of discovery research at Amylin Pharmaceuticals and former senior faculty at Imperial College in Cambridge, UK.